U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07174141) titled 'Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study' on Sept. 04.
Brief Summary: Second-generation Bruton's tyrosine kinase inhibitors (BTKIs) (zanubrutinib, acalabrutinib) are recently discovered oral targeted therapies used to treat hematological disorders such as chronic lymphocytic leukemia, mantle cell lymphoma, non-Hodgkin's lymphoma, and Waldenstrom's macroglobulinemia.
These treatments significantly increase survival rates for these diseases, but over the years, we have observed the emergence of cardiovascular adve...